Related Experiment Video

Updated: Aug 20, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Ublituximab: a new anti-CD20 agent for multiple sclerosis

Jiwon Oh1, Amit Bar-Or2

  • 1Division of Neurology, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto M5B1W8, ON, Canada; Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.

The Lancet. Neurology
|November 19, 2022
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.3K
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

1.9K

Related Experiment Videos

Last Updated: Aug 20, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.3K
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

1.9K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

211
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
211
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

248
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
248

Articles linked to this work by shared authors, journal, and citation graph.

Abnormal B-Cell Exosome Proapoptotic and Antiapoptotic Cargo in Multiple Sclerosis: Potential Implication in Progressive Disease Biology.

Neurology(R) neuroimmunology & neuroinflammation·2026

Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.

The Lancet. Neurology·2026

Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.

European journal of neurology·2026

Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.

Lancet (London, England)·2026

The Effect of Ocrelizumab on Anti-JC Virus Antibody Index.

Brain and behavior·2026

The gut microbiome in pediatric-onset acquired demyelinating syndromes by myelin oligodendrocyte glycoprotein antibody status.

Multiple sclerosis and related disorders·2026

Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial.

The Lancet. Neurology·2026

Deep brain stimulation for the treatment of patients with dystonia: advances towards network-based personalised care.

The Lancet. Neurology·2026

The role of the gut microbiome in mediating neuroinflammation in immune-based neurological disorders.

The Lancet. Neurology·2026

Parkinson's disease genetics across diverse ancestries: an observational genetic study of causal and risk variants with translational implications.

The Lancet. Neurology·2026

Survival estimates and their predictors in genetic frontotemporal dementia: an international, retrospective, cohort study.

The Lancet. Neurology·2026

Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.

The Lancet. Neurology·2026

Quantitative 99mTc-Pyrophosphate SPECT/CT evaluation of tafamidis response in a case of transthyretin cardiac amyloidosis.

Asia Oceania journal of nuclear medicine & biology·2026

T cell antigenic recognition sequencing (TAR-seq) enables precise characterization of vaccine-elicited cellular immunity ex vivo and in vivo.

Frontiers in immunology·2026

Ocular surface and meibomian gland changes following repeated exposure to 5% povidone-iodine during intravitreal injections.

Eye (London, England)·2026

Fc-optimized GITR antibody enhances a CD4 T cell-dendritic cell crosstalk to promote antitumor immunity.

Nature cancer·2026

Network meta-analysis of triple immunosuppressive therapies and standard of care for induction of remission of active lupus nephritis.

Lupus·2026

[Expert suggestions on clinical practice for telitacicept in the treatment of IgA nephropathy (2026 edition)].

Zhonghua nei ke za zhi·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us